Percheron Therapeutics (ASX:PER) 6-Month Share Buyback Ratio : -20.62% (As of Dec. 2024 )

View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Percheron Therapeutics's current 6-Month Share Buyback Ratio was -20.62%.

Competitive Comparison of Percheron Therapeutics's 6-Month Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Percheron Therapeutics's 6-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Percheron Therapeutics 6-Month Share Buyback Ratio Calculation

Percheron Therapeutics's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(901.545	-	1087.438)	/	901.545
	=	-20.62%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics (ASX:PER) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Percheron Therapeutics 6-Month Share Buyback Ratio Related Terms

Percheron Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

AWY0:Germany

Address

14 Wallace Avenue, LEVEL 1, Toorak, VIC, AUS, 3142

Website

https://www.percherontx.com

Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.

Percheron Therapeutics Headlines

No Headlines